Molnupiravir has provisional approval for the treatment of adults with COVID 19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk for hospitalisation or death [see Dosage & Administration and Pharmacology: Pharmacodynamics: Clinical efficacy and safety under Actions].